AUA 2023 Bladder Cancer

Viewing 1-20 of 37 articles

AUA 2023: An Interim Analysis of a Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients With BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) Carcinoma in-situ (CIS)

AUA 2023: Bladder Preservation in Muscle Invasive Bladder Cancer: Myth or Reality

AUA 2023: Very High Risk NMIBC: Radical Cystectomy or Intravesical Therapy

AUA 2023: Outcomes and Genomic Characteristics of Newly Diagnosed High Grade Ta Papillary Urothelial Carcinoma Treated with Intravesical Chemotherapy vs BCG: A Comparative Study During the BCG Shortage

AUA 2023: Chemotherapy Vs Immunotherapy as Neoadjuvant Therapies in Cisplatin-Eligible Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer

AUA 2023: Evaluation of Gender Specific Differences in Health-Related Quality of Life for Bladder Cancer Patients After Radical Cystectomy - Results From a Large Prospective Propensity Score-Matched Cohort

AUA 2023: Optimizing BCG Therapy/Managing BCG Toxicity

AUA 2023: Biology and Performance of Pre- and Post- Pembrolizumab Vesical Imaging-reporting and Data System to Predict the Pathological Response in Muscle-invasive Urothelial Bladder Cancer: Full Data Analysis From a Clinical Trials Pipeline

AUA 2023: Pembrolizumab for Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin : Efficacy and Evaluation of Subsequent Cystectomy From Cohort B of the Phase 2 KEYNOTE-057 Study

AUA 2023: What is the "Best" Diversion: Conduit or Neobladder?

AUA 2023: Optimal TURBT: Do Skilled Urologists Really Need PDD?

AUA 2023: Pathology or 'Markers': What is More Important?

AUA 2023: Results From the Extended Follow-up in Patients With Muscle-Invasive Bladder Cancer in the Checkmate 274 Trial

AUA 2023: Optimal Management of cN+ Muscle Invasive Bladder Cancer

AUA 2023: Intermediate Risk NMIBC: Surveillance and Treatment Challenges

AUA 2023: Perioperative Outcomes of Radical Cystectomy Following Neoadjuvant Gemcitabine, Cisplatin and Atezolizumab

AUA 2023: The Effects of Sequential Mitomycin and BCG Treatment Versus BCG Monotherapy in Patients With High-risk Non-muscle Invasive Bladder Cancer: MITO-BCG

AUA 2023: First Results from SunRISe-1 in Patients with BCG Unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Receiving TAR-200 in Combination With Cetrelimab, TAR-200, or Cetrelimab Alone

AUA 2023: Optimizing Care of Bladder Cancer in Women

AUA 2023: Complete Pathological Response in Patients Undergoing Nephrectomy for RCC Following Immune Checkpoint Inhibitor Therapy: A Multicenter Study

1
2